Endocrine Abstracts

Context: Amiodarone is a widely used anti-arrhythmic medication, however associated with a 15-20% rate of thyroid adverse effects. Amiodarone-induced thyrotoxicosis (AIT) is a complex disease due to diagnostic difficulties and therapeutic challenges. AIT patients often receive initial therapy for thyrotoxicosis before admission to a referral center. Whether the first-line medical therapy (i.e. therapies for thyrotoxicosis at first diagnosis of AIT) may affect the outcome of AI...

The insulin-like growth factor-1 receptor (IGF-1R) is involved in the pathogenesis of Graves’ orbitopathy (GO) and a possible protective role of autoantibodies against IGF-1R (IGF-1R-Abs) has been suggested. We conducted a cross-sectional study to investigate IGF-1R-Abs serum levels in 147 consecutive patients with Graves’ disease (GD), with (n = 92) or without (n = 55) GO (primary outcome). Secondary outcomes were: 1) relationship between IGF-1R-Ab...

We report the clinical history of a 21-years old young female who, in February 2021, presented abdominal pain and biliary vomiting that lasted for two months. An esophagus-gastroduodenoscopy revealed a duodenal ulcerative lesion and proton pump inhibitory therapy was started with clinical benefit. One month later, the patient presented a facial acneiform rush with hirsutism for which she was referred to our attention. An abdominal MRI documented a well-circumscribed hyper-vasc...

Context: Programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) are key regulators in T-cell activation and tolerance. Nivolumab (PD-1 inhibitor) and Atezolizumab (PD-L1 inhibitor) are monoclonal antibodies approved for the treatment of several types of advanced cancers. Immune checkpoint inhibition caused by these drugs can result in immune-related adverse events (irAEs) New-onset diabetes mellitus has been reported in fewer than 1% of patients an...

Objectives: Optimal treatment for Graves’ hyperthyroidism (GH) in patients with moderate-to-severe, active Graves’ orbitopathy (GO) remains to be established. There is debate on whether a conservative (antithyroid drugs, ATDs) or an ablative approach (radioactive iodine, RAI, or surgery, Tx)has to be preferred. The aim of the present study was to investigate whether these different approachesresult in a different outcome of GOfollowing intravenous glucocorticoids (iv...

Objectives: Sirolimus is an immunosuppressive drug with anti-fibrotic and anti-proliferative activities. In a recent study, sirolimus (given off-label as a second-line treatment) was found to be associated with a better outcome of Graves’ orbitopathy (GO) at 6 months compared to the standard treatment (intravenous glucocorticoids). Here we investigated the effects of sirolimus over a longer period of time.Methods: The study design entailed data anal...

Objectives: Sirolimus is an immunosuppressive drug with anti-fibrotic and anti- proliferative activities. Recently, sirolimus (given off-label as a second-line treatment) was found to be associated with a better outcome of Graves’ orbitopathy (GO) at 24 weeks compared to methylprednisolone. Here we conducted a retrospective study to investigate the efficacy and safety of sirolimus compared with methylprednisolone over a longer period of time.Methods...